FAQ

refametinib

An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein… (More)

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Related topics

Related topics

1 relation

Narrower (1)

RDEA 119

Related mentions per year

Related mentions per year

2010-2017
201020122014201620182020
refametinib
RDEA 119

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
Purpose The MEK/MAPK pathway is commonly activated in HER2-positive breast cancer, but little investigation of targeting this… (More)
Is this relevant?
2017
2017
Inhibition of MAPK‐Erk pathway in vivo attenuates aortic valve disease processes in Emilin1‐deficient mouse model
Aortic valve disease (AVD) is a common condition with a progressive natural history, and presently, there are no pharmacologic… (More)
Is this relevant?
2016
2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer
Activating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part of the MAPK… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2016
2016
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
PURPOSE To assess the safety and tolerability of the small-molecule allosteric MEK inhibitor refametinib combined with sorafenib… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.
Advanced or recurrent low-grade serous ovarian cancers (LGSC) are resistant to conventional systemic treatments. LGSC carry… (More)
Is this relevant?
2015
2015
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
The multikinase inhibitor regorafenib (BAY 73-4506) exerts both anti-angiogenic and anti-tumorigenic activity in adult solid… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 2
Is this relevant?
2014
2014
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
PURPOSE There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2014
2014
Cancer Therapy: Clinical APhase II Study of theEfficacy andSafety of theCombination Therapy of theMEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable…
Purpose: There is an unmet need for treatment options in hepatocellular carcinoma (HCC). Sorafenib is currently the only approved… (More)
  • table 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2013
2013
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
OBJECTIVE The objectives of the study were to evaluate the allosteric mitogen-activated protein kinase kinase (MEK) inhibitor BAY… (More)
Is this relevant?
Review
2013
Review
2013
MEK and the inhibitors: from bench to bedside
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?